According to the charity, FIP, which is one of a number of chronic viral infections of cats that resemble those in people, is estimated to kill up to 1.4% of cats around the world.
The infectious agent is a mutant coronavirus (FIPV) that is notoriously difficult to control: the parent enteric coronavirus is present in virtually all catteries and shelters and is shed by 60% or more of pet cats from multi-cat households,1 and vaccines are ineffective.
Among the most promising treatments against emerging viruses in humans is 'GS-5734', one of the small-molecule antivirals targeting specific proteins involved in RNA virus replication.
In studies, it has proven effective in preventing Ebola in rhesus monkeys and inhibiting coronaviruses both in tissue culture and in mouse infection models.
It was these findings that brought it to the attention of a team of veterinary researchers in the USA, led by Professor Niels Pedersen of the University of California, Davis.
Their own initial studies involving experimental FIP showed that the less chemically complex 'GS-441524', the parent nucleoside of GS-5734, was highly effective, opening the way for a field trial in cats with naturally occurring FIP, the results of which are published in this week's JFMS2.
Thirty-one cats, ranging in age from 3–73 months, were enrolled in the study, and 26 completed the planned 12 weeks or more of treatment; the remainder died or were euthanised due to their severe disease.
For these 26 cats, the clinical response was dramatic: fever usually resolved within 12–36 h, concurrent with a marked improvement in appetite, activity levels and weight gain.
In cats with the more common effusive or ‘wet’ form of FIP, abdominal effusions rapidly disappeared, starting at around 10–14 days after commencing treatment.
Encouragingly, and somewhat unexpectedly, cats with non-effusive (‘dry’) FIP and older cats responded as well to GS-441524 treatment as did cats with effusive FIP and young cats. The safety profile of GS-441524 was likewise impressive.
Currently, 24 of the 26 cats remain healthy, with one having succumbed to FIP disease and one to unrelated heart disease. Eighteen of these cats underwent just one round of treatment; the remaining eight suffered disease relapses, but these were successfully treated with a further (in two cases, a third) round of treatment at a higher dose.
Previously the prospects for cats with FIP were bleak. In a review paper on FIP published in JFMS a decade ago, Professor Pedersen stated: "no treatment has proven effective in curing cats of FIP, in spite of the claims. Cats that develop FIP inevitably die of their disease in days, weeks or months."1
Now, as he approaches the end of his professional career, Professor Pedersen is considerably more optimistic: "FIP has been my fascination for the past 50 years and I am fortunate to have reached a final stage in my career having identified safe and effective antiviral drugs. We now know that small molecules targeting specific steps in RNA virus replication are capable of safely curing various forms of FIP."
However, he cautioned: "It must be emphasised that the field trial we report was for proof-of-concept and the results cannot be immediately translated into commercially available products.
"Unfortunately, the real hope provided by these initial trials has increased, and not decreased, the desperation of owners to seek out these new drugs on the black market. As eventful as these discoveries may be, there is still much more about FIP to discover.
"I would like to thank all of the people, organizations and owners who have assisted in my research over this half century and leave remaining questions and associated discoveries for my fellow FIP researchers."
Reference
Photo: Bubba, one of the study cats, in recovery. Courtesy Adel Gastle
PS: Whilst you're here, take a moment to see our latest job opportunities for vets.